Harbin Gloria Pharmaceuticals Co., Ltd (002437.SZ)
CNY 2.69
(-0.74%)
CNY 2.69
(-0.74%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 190.66 Million CNY | -10.96% |
| 2022 | 214.13 Million CNY | -39.18% |
| 2021 | 352.09 Million CNY | -5.09% |
| 2020 | 370.95 Million CNY | -18.58% |
| 2019 | 455.63 Million CNY | 2.08% |
| 2018 | 446.33 Million CNY | -4.9% |
| 2017 | 469.31 Million CNY | 73.01% |
| 2016 | 271.25 Million CNY | -2.22% |
| 2015 | 277.42 Million CNY | 69.73% |
| 2014 | 163.44 Million CNY | 35.55% |
| 2013 | 120.58 Million CNY | 78.54% |
| 2012 | 67.53 Million CNY | -6.81% |
| 2011 | 72.47 Million CNY | 36.06% |
| 2010 | 53.26 Million CNY | 126.0% |
| 2009 | 23.56 Million CNY | 18.21% |
| 2008 | 19.93 Million CNY | 34.89% |
| 2007 | 14.77 Million CNY | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 189.03 Million CNY | -0.86% |
| 2024 Q2 | 185.34 Million CNY | -1.95% |
| 2024 Q3 | 187.62 Million CNY | 1.23% |
| 2023 Q3 | 206.4 Million CNY | 0.92% |
| 2023 Q4 | 190.66 Million CNY | -7.62% |
| 2023 FY | 190.66 Million CNY | -10.96% |
| 2023 Q1 | 216.14 Million CNY | 0.94% |
| 2023 Q2 | 204.52 Million CNY | -5.37% |
| 2022 Q3 | 256.64 Million CNY | -8.66% |
| 2022 FY | 214.13 Million CNY | -39.18% |
| 2022 Q4 | 214.13 Million CNY | -16.56% |
| 2022 Q2 | 280.96 Million CNY | -18.42% |
| 2022 Q1 | 344.4 Million CNY | -2.18% |
| 2021 FY | 352.09 Million CNY | -5.09% |
| 2021 Q4 | 352.09 Million CNY | -18.85% |
| 2021 Q1 | 384.69 Million CNY | 3.7% |
| 2021 Q2 | 438.87 Million CNY | 14.08% |
| 2021 Q3 | 433.88 Million CNY | -1.14% |
| 2020 Q2 | 485.28 Million CNY | -3.25% |
| 2020 Q4 | 370.95 Million CNY | -27.21% |
| 2020 FY | 370.95 Million CNY | -18.58% |
| 2020 Q1 | 501.56 Million CNY | 10.08% |
| 2020 Q3 | 509.6 Million CNY | 5.01% |
| 2019 Q1 | 471.06 Million CNY | 5.54% |
| 2019 FY | 455.63 Million CNY | 2.08% |
| 2019 Q4 | 455.63 Million CNY | 2.51% |
| 2019 Q3 | 444.48 Million CNY | -4.59% |
| 2019 Q2 | 465.87 Million CNY | -1.1% |
| 2018 Q4 | 446.33 Million CNY | -3.45% |
| 2018 Q3 | 462.26 Million CNY | -3.68% |
| 2018 FY | 446.33 Million CNY | -4.9% |
| 2018 Q1 | 490.74 Million CNY | 4.57% |
| 2018 Q2 | 479.92 Million CNY | -2.21% |
| 2017 Q4 | 469.31 Million CNY | 35.24% |
| 2017 FY | 469.31 Million CNY | 73.01% |
| 2017 Q1 | 284.67 Million CNY | 4.95% |
| 2017 Q2 | 313.57 Million CNY | 10.15% |
| 2017 Q3 | 347.02 Million CNY | 10.67% |
| 2016 Q2 | 337.5 Million CNY | 8.8% |
| 2016 Q1 | 310.21 Million CNY | 11.82% |
| 2016 Q4 | 271.25 Million CNY | -12.17% |
| 2016 Q3 | 308.84 Million CNY | -8.49% |
| 2016 FY | 271.25 Million CNY | -2.22% |
| 2015 Q1 | 243.7 Million CNY | 49.11% |
| 2015 FY | 277.42 Million CNY | 69.73% |
| 2015 Q3 | 258.46 Million CNY | 13.82% |
| 2015 Q4 | 277.42 Million CNY | 7.33% |
| 2015 Q2 | 227.07 Million CNY | -6.82% |
| 2014 Q4 | 163.44 Million CNY | -10.11% |
| 2014 Q3 | 181.81 Million CNY | -4.13% |
| 2014 FY | 163.44 Million CNY | 35.55% |
| 2014 Q1 | 179.18 Million CNY | 48.6% |
| 2014 Q2 | 189.64 Million CNY | 5.84% |
| 2013 Q2 | 125.83 Million CNY | 26.46% |
| 2013 Q4 | 120.58 Million CNY | -10.04% |
| 2013 FY | 120.58 Million CNY | 78.54% |
| 2013 Q1 | 99.5 Million CNY | 47.33% |
| 2013 Q3 | 134.03 Million CNY | 6.52% |
| 2012 Q4 | 67.53 Million CNY | -19.6% |
| 2012 FY | 67.53 Million CNY | -6.81% |
| 2012 Q3 | 84 Million CNY | 27.12% |
| 2012 Q2 | 66.08 Million CNY | -9.61% |
| 2012 Q1 | 73.11 Million CNY | 0.88% |
| 2011 Q3 | 74.87 Million CNY | 12.95% |
| 2011 Q1 | 57.47 Million CNY | 7.9% |
| 2011 Q4 | 72.47 Million CNY | -3.21% |
| 2011 FY | 72.47 Million CNY | 36.06% |
| 2011 Q2 | 66.29 Million CNY | 15.35% |
| 2010 Q2 | 30.41 Million CNY | -25.01% |
| 2010 Q3 | 41.33 Million CNY | 35.88% |
| 2010 Q4 | 53.26 Million CNY | 28.86% |
| 2010 FY | 53.26 Million CNY | 126.0% |
| 2010 Q1 | 40.56 Million CNY | 72.12% |
| 2009 Q4 | 23.56 Million CNY | 0.0% |
| 2009 FY | 23.56 Million CNY | 18.21% |
| 2008 FY | 19.93 Million CNY | 34.89% |
| 2007 FY | 14.77 Million CNY | 0.0% |